Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-07-26 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges, informing about the incorporation of a wholly owned subsidiary approved by the Board of Directors. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events disclosures. The document is brief (1570 characters) and does not contain financial data, detailed reports, or management discussion. It is an announcement of a corporate event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-26 English
Lupin Receives Approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of regulatory approval from the Therapeutic Goods Administration (TGA) Australia for a pharmaceutical product (Tiotropium Dry Powder for Inhaler). It is addressed to stock exchanges and includes a summary of the product, its indication, and company background. There are no financial statements, detailed financial performance data, or management discussion of results. The document is a disclosure pursuant to a listing regulation (Regulation 30 of SEBI Listing Obligations and Disclosure Requirements), which typically covers material events or information updates. The document length is about 5,171 characters, which is relatively short and consistent with a press release or regulatory announcement rather than a full report. It does not contain financial data or detailed analysis, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it is the actual announcement itself. The content fits best with a Regulatory Filing (RNS) as it is a regulatory disclosure about a material event (product approval) relevant to investors and the market but not a financial report or management change. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-07-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of regulatory approval from the Therapeutic Goods Administration (TGA) Australia for a pharmaceutical product (Tiotropium Dry Powder for Inhaler). It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the approval event and product details rather than financial results, management changes, or detailed financial data. The document length is about 5,178 characters, which is relatively short and typical for a press release. There is no indication of financial statements, earnings data, or detailed report content. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and disclosure pursuant to listing obligations, not a financial report or other specific filing type.
2023-07-26 English
Earnings Call Q1 FY24.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the scheduling of an earnings call for Q1 FY24. It references the SEBI regulations for disclosure and mentions that transcripts of the call will be filed later. The document includes details about the date and time of the call and instructions to join via Zoom. The document length is short (1538 characters) and does not contain any financial data or results itself, only an announcement of the upcoming earnings call. Therefore, it is not the earnings release or the transcript but an announcement related to the earnings call. According to the filing definitions and rules, this fits best under Regulatory Filings (RNS) as a general regulatory announcement about the earnings call schedule and transcript filing.
2023-07-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a short notice informing stock exchanges about the scheduling of an earnings call for Q1 FY24. It references the upcoming earnings call and mentions that transcripts will be filed later. There is no actual financial data or detailed financial results presented in this document. The length is only 1594 characters, which is quite short and consistent with an announcement rather than a full report or transcript. According to the rules, announcements about earnings calls or their scheduling are best classified as Call Transcript (CT) if they contain the transcript, but this document only announces the call, not the transcript itself. However, since the document is specifically about the earnings call event and not the earnings release or transcript, the best fit is Call Transcript (CT) category as it relates to the earnings call event. Confidence is high due to clear mention of earnings call and regulatory references.
2023-07-24 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaboration between Lupin Digital Health and the American College of Cardiology to deliver in-home cardiovascular care with digital therapeutics in India. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, which relates to material events or information. The content focuses on a business collaboration and innovation in healthcare delivery, not on financial results, management changes, or regulatory filings. It is not a financial report, earnings release, management discussion, or any other detailed report type. The document is a corporate announcement of a significant business development, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2023-07-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.